0383 (0383) Fair Value & Analysis

Healthcare · Market cap HK$859M

0 0383 0383 · HK

PriceHK$0.8500

Fair ValueHK$0.7400

Upside-12.9%

Quality39/100

Evidence: Medium Range HK$0.5200 – HK$0.9700

Fair value as of: Jul 1, 2026

From 8 valuation models · updated today

Share price −19.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.8000 – HK$1.14 · fair‑value band HK$0.5200 – HK$0.9700 · the HK$0.8500 price screens above the HK$0.7400 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0383 (0383) currently trades at HK$0.8500, while our model-based Fair Value estimate is HK$0.7400 — implying the stock looks roughly 12.9% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 0383 generated revenue of HK$1.6B at a net margin of -1.6%. Revenue grew 6.1% year over year. It earns a return on equity of -1.1%. Net debt stands at HK$149M. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$1.6B

Revenue growth (YoY) +6.1%

Net margin -1.6%

Return on equity -1.1%

Free cash flow −HK$69.2M FY2026

Operating margin 2.8%

More key figures

EPS (TTM) HK$0.0100

EPS growth (YoY) -44.6%

Net debt HK$149M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

0383 reported revenue of HK$1.6B in FY2026 versus HK$1.5B in FY2022, a compound +2.9%/yr. Reported net income was −HK$26.8M in FY2026.

Revenue +2.9%/yr

FY22 HK$1.5B

FY23 HK$1.4B

FY24 HK$1.6B

FY25 HK$1.6B

FY26 HK$1.6B

Net income

FY22 −HK$137M

FY23 −HK$124M

FY24 HK$11.3M

FY25 HK$28.8M

FY26 −HK$26.8M

Is 0383 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$96.00	R$25.67	-73%
Fresenius SE FSNUY	$11.27	$8.25	-27%
5225 5225	8.70 MYR	2.61 MYR	-70%
IHHHF IHHHF	$1.71	$1.26	-26%
Tenet Healthcare Corporation THC	$178.75	$300.86	+68%
Rede D'Or São Luiz S.A RDOR3	R$33.83	R$46.94	+39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0383 (0383) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$0.7400 versus a price of HK$0.8500 — about −13% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0383?

Our model-based fair value for 0383 is HK$0.7400 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$0.8500.

What is the quality score of 0383?

0383 has a Quality Score of 39/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0383 (0383)?

0383 reported trailing-twelve-month revenue of about HK$1.6B (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0383?

The net profit margin of 0383 is about -1.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.